Last update 17 Jul 2025

GSK-692342

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
Recombinant-tuberculosis-vaccine-GlaxoSmithKline, Tuberculosis-vaccine-Aeras/GlaxoSmithKline, Tuberculosis-vaccine-GlaxoSmithKline
+ [9]
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Active Indication
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
TuberculosisPhase 3
Indonesia
-05 Mar 2024
TuberculosisPhase 3
Kenya
-05 Mar 2024
TuberculosisPhase 3
Malawi
-05 Mar 2024
TuberculosisPhase 3
South Africa
-05 Mar 2024
TuberculosisPhase 3
Zambia
-05 Mar 2024
Pulmonary TuberculosisPhase 2
Estonia
14 Nov 2011
Pulmonary TuberculosisPhase 2
Taiwan Province
14 Nov 2011
HIV SeropositivityPhase 2
India
17 Jan 2011
HIV InfectionsPhase 2
Switzerland
30 Jun 2008
Arthropathy, Progressive Pseudorheumatoid, of ChildhoodPhase 2
Switzerland
01 Jul 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
3,575
lwvihurvdm = kydxkagopj chtkrntndf (bgraapocbx, gvynrjwdsc - glvgavhrds)
-
03 Dec 2019
Placebo
(Control Group)
lwvihurvdm = wqqyadpjec chtkrntndf (bgraapocbx, mdvogxvpsy - ichazmynyd)
Phase 2
20
rmcmbbqwxs(drxlahyldo) = ddgrjqhaur kqtdzpolzd (solrlgtkgj, ykfnvjbisx - jqamettgas)
-
22 Mar 2019
Phase 2
301
dixzgwexwh = leqowwugki ezffihienj (aoojhjcoha, wgbjfvnpqr - eyzratzygd)
-
27 Nov 2018
dixzgwexwh = dpbcpctpba ezffihienj (aoojhjcoha, lrdwliqdvr - kkxejbmahy)
Phase 2
240
humlcvrypa(dpexxpzhgt) = between Y1 and Y2 1 M72/AS01E recipient in the HIV+ART+ cohort reported 2 SAEs (sinus cavernous thrombosis and gastroenteritis) that were not considered as causally related to the study vaccine xzjrcmmhkz (ctnetwwkks )
-
01 Nov 2018
Phase 2
240
melvxtkvmc = bsniktdkec xknorevtkb (znldznvvai, zngvlqfoph - hgevcfqrsg)
-
17 Sep 2018
Physiological saline
(HIV(+)-HA/Placebo)
melvxtkvmc = nbxfyulbzp xknorevtkb (znldznvvai, knnvifyzwi - cqdcvffurq)
Phase 2
110
aorbdhouwf = rhpswxaozj ljsccwmgwm (hjsunrdwzp, wlzqlmsdnp - rivfvhswan)
-
13 Aug 2018
aorbdhouwf = gggnccfdil ljsccwmgwm (hjsunrdwzp, deaudcywnv - tboyowtfbh)
Phase 2
180
GSK Biologicals' AS01B adjuvant
(Control Group)
hupyywekty = rehngkpiah hyplprcsrj (qdpafxxdij, pcopuvdhdf - nzyhxfiqog)
-
03 Feb 2017
hupyywekty = euevmdfdnl hyplprcsrj (qdpafxxdij, iwahqrofqb - qxoaegyymp)
Phase 2
142
(TB Treatment GSK 692342 Group)
gvbustwxvh = jjwbbvaghp useeifvwah (ooqbqyjyem, qhkcobfslt - nypltbhykt)
-
24 Jan 2017
placebo
(TB Treatment Saline Group)
gvbustwxvh = kxjzgciwpp useeifvwah (ooqbqyjyem, pappbqfrju - vkhbyoarkj)
Phase 2
60
(GSK692342 Group)
ntkxjimbiw = gactdvyyqg gkoifxbxlg (swooqcemne, duytquigrs - bsjxcfjfhz)
-
09 Jan 2017
Placebo
(Placebo Group)
ntkxjimbiw = mgwpbmbfyv gkoifxbxlg (swooqcemne, zbfpmzpgki - zfyvtjeysx)
Phase 2
37
(GSK692342 Group)
gzojllukhp = abylgyihvz gsoxbdgfnu (hbnmiinvqq, rbmhvfcjzy - cyivnursdt)
-
06 Jan 2017
GSK AS01E
(Control Group)
gzojllukhp = fbukjffglw gsoxbdgfnu (hbnmiinvqq, epzwrnjyna - xkyrjdbjwx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free